Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bernhard Englinger, Ph.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Englinger B, Hack OA, Filbin MG. Into Thin Air: Hypoxia Drives Metabolic and Epigenomic Deregulation of Lethal Pediatric Ependymoma. Dev Cell. 2020 Jul 20; 54(2):134-136. PMID: 32693052.
    Citations:    
  2. Gojo J, Englinger B, Jiang L, Hübner JM, Shaw ML, Hack OA, Madlener S, Kirchhofer D, Liu I, Pyrdol J, Hovestadt V, Mazzola E, Mathewson ND, Trissal M, Lötsch D, Dorfer C, Haberler C, Halfmann A, Mayr L, Peyrl A, Geyeregger R, Schwalm B, Mauermann M, Pajtler KW, Milde T, Shore ME, Geduldig JE, Pelton K, Czech T, Ashenberg O, Wucherpfennig KW, Rozenblatt-Rosen O, Alexandrescu S, Ligon KL, Pfister SM, Regev A, Slavc I, Berger W, Suvà ML, Kool M, Filbin MG. Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell. 2020 Jul 13; 38(1):44-59.e9. PMID: 32663469.
    Citations:    
  3. Guntner AS, Peyrl A, Mayr L, Englinger B, Berger W, Slavc I, Buchberger W, Gojo J. Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathol Commun. 2020 06 03; 8(1):78. PMID: 32493453.
    Citations:    
  4. Englinger B, Laemmerer A, Moser P, Kallus S, Röhrl C, Pirker C, Baier D, Mohr T, Niederstaetter L, Meier-Menches SM, Gerner C, Gabler L, Gojo J, Timelthaler G, Senkiv J, Jäger W, Kowol CR, Heffeter P, Berger W. Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. Int J Cancer. 2020 Sep 15; 147(6):1680-1693. PMID: 32064608.
    Citations:    
  5. Domarco O, Kieler C, Pirker C, Dinhof C, Englinger B, Reisecker JM, Timelthaler G, García MD, Peinador C, Keppler BK, Berger W, Terenzi A. Subcellular Duplex DNA and G-Quadruplex Interaction Profiling of a Hexagonal PtII Metallacycle. Angew Chem Int Ed Engl. 2019 06 11; 58(24):8007-8012. PMID: 31002438.
    Citations:    
  6. Englinger B, Kallus S, Senkiv J, Laemmerer A, Moser P, Gabler L, Groza D, Kowol CR, Heffeter P, Grusch M, Berger W. Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074. Cells. 2018 Dec 08; 7(12). PMID: 30544798.
    Citations:    
  7. Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, Berger W. Metal Drugs and the Anticancer Immune Response. Chem Rev. 2019 01 23; 119(2):1519-1624. PMID: 30489072.
    Citations:    
  8. Alonso-de Castro S, Terenzi A, Hager S, Englinger B, Faraone A, Martínez JC, Galanski M, Keppler BK, Berger W, Salassa L. Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis. Sci Rep. 2018 11 21; 8(1):17198. PMID: 30464209.
    Citations:    
  9. Kallus S, Englinger B, Senkiv J, Laemmerer A, Heffeter P, Berger W, Kowol CR, Keppler BK. Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. Nanomedicine. 2018 11; 14(8):2632-2643. PMID: 30121385.
    Citations:    
  10. Heilos D, Röhrl C, Pirker C, Englinger B, Baier D, Mohr T, Schwaiger M, Iqbal SM, van Schoonhoven S, Klavins K, Eberhart T, Windberger U, Taibon J, Sturm S, Stuppner H, Koellensperger G, Dornetshuber-Fleiss R, Jäger W, Lemmens-Gruber R, Berger W. Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins. Oncotarget. 2018 May 22; 9(39):25661-25680. PMID: 29876015.
    Citations:    
  11. Kiakos K, Englinger B, Yanow SK, Wernitznig D, Jakupec MA, Berger W, Keppler BK, Hartley JA, Lee M, Patil PC. Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA. Bioorg Med Chem Lett. 2018 05 01; 28(8):1342-1347. PMID: 29548574.
    Citations:    
  12. Mayr L, Pirker C, Lötsch D, Van Schoonhoven S, Windhager R, Englinger B, Berger W, Kubista B. CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model. Oncotarget. 2017 Dec 26; 8(69):114095-114108. PMID: 29371972.
    Citations:    
  13. Englinger B, Kallus S, Senkiv J, Heilos D, Gabler L, van Schoonhoven S, Terenzi A, Moser P, Pirker C, Timelthaler G, Jäger W, Kowol CR, Heffeter P, Grusch M, Berger W. Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. J Exp Clin Cancer Res. 2017 09 07; 36(1):122. PMID: 28882160.
    Citations:    
  14. Heilos D, Rodríguez-Carrasco Y, Englinger B, Timelthaler G, van Schoonhoven S, Sulyok M, Boecker S, Süssmuth RD, Heffeter P, Lemmens-Gruber R, Dornetshuber-Fleiss R, Berger W. The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study. Toxins (Basel). 2017 08 24; 9(9). PMID: 28837057.
    Citations:    
  15. Englinger B, Mair M, Miklos W, Pirker C, Mohr T, van Schoonhoven S, Lötsch D, Körner W, Ferk F, Knasmüller S, Heffeter P, Keppler BK, Grusch M, Berger W. Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. Br J Cancer. 2017 Feb 14; 116(4):489-500. PMID: 28095394.
    Citations:    
  16. Englinger B, Lötsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B, Lardeau CH, Spitzwieser M, Szabó P, Heffeter P, Lang I, Cichna-Markl M, Grasl-Kraupp B, Marian B, Grusch M, Kubicek S, Szakács G, Berger W. Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. Oncotarget. 2016 Aug 02; 7(31):50161-50179. PMID: 27367030.
    Citations:    
  17. Kryeziu K, Pirker C, Englinger B, van Schoonhoven S, Spitzwieser M, Mohr T, Körner W, Weinmüllner R, Tav K, Grillari J, Cichna-Markl M, Berger W, Heffeter P. Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. Oncotarget. 2016 May 10; 7(19):27379-93. PMID: 27036042.
    Citations:    
  18. Miklos W, Pelivan K, Kowol CR, Pirker C, Dornetshuber-Fleiss R, Spitzwieser M, Englinger B, van Schoonhoven S, Cichna-Markl M, Koellensperger G, Keppler BK, Berger W, Heffeter P. Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. Cancer Lett. 2015 May 28; 361(1):112-20. PMID: 25749419.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Englinger's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (98)
Explore
_
Co-Authors (9)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.